Cogent Biosciences, Inc. (COGT)

The past six months have been marked by several significant events that have positively impacted Cogent Biosciences' stock price. In November 2025, Cogent reported positive top-line results from the Phase 3 PEAK trial of bezuclastinib in combination with sunitinib for GIST patients and completed public offerings generating approximately $546.8 million. In December 2025, the company submitted its NDA to the FDA for bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) and announced initial preclinical results for its JAK2 V617F inhibitor (CGT1145). In February 2026, Cogent provided a business update and reported strong financial results for 2025, highlighting the SUMMIT NDA submission and the initiation of the PEAK NDA under the FDA's RTOR program and BTD. In March 2026, the FDA accepted the NDA for bezuclastinib in patients with NonAdvanced Systemic Mastocytosis. In April 2026, Cogent announced the submission of its NDA for bezuclastinib in GIST and positive Phase 3 PEAK trial data in GIST was selected for oral presentation at ASCO. In May 2026, the company reported recent business highlights and first-quarter 2026 financial results, indicating that multiple NDAs for bezuclastinib are under FDA review, with a PDUFA date of December 30, 2026, for NonAdvSM, and ended Q1 2026 with $866.4 million in cash, expected to fund operations into 2028.

Cogent Biosciences, as a clinical-stage biotechnology company, does not currently experience traditional demand seasonality as it does not sell approved commercial products. Its value is tied to its investigational medicines and clinical development programs. The company anticipates a commercial launch of bezuclastinib in the second half of 2026, contingent on regulatory approval.

Cogent Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases, particularly in precision oncology. Its core business involves discovering and developing targeted small-molecule drugs for specific oncogenic and hematologic driver mutations. The company's lead program is bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor targeting the KIT D816V mutation in systemic mastocytosis (SM) and KIT exon 17 mutations in advanced gastrointestinal stromal tumors (GIST). Cogent is also developing a pipeline of novel targeted therapies, including inhibitors for FGFR2/3, pan-KRAS(ON), JAK2 V617F, mutant ErbB2, and PI3Kα.

Cogent Biosciences is headquartered in Waltham, Massachusetts, and has operations in Boulder, Colorado. While the company conducts global clinical trials, its primary operational and corporate footprint is concentrated within the United States.

Cogent Biosciences has a positive brand reputation in the biotechnology sector, particularly in precision medicine, driven by its commitment to clinical development and addressing unmet medical needs in genetically defined diseases. The advancement of bezuclastinib through positive pivotal trials and NDA submissions has bolstered its standing, further underscored by the granting of Breakthrough Therapy Designation. Consistent positive clinical and regulatory milestones have reinforced its image as a strong contender in the precision therapy space.

Cogent Biosciences has a diverse ownership structure with significant institutional, individual, and retail investor participation. As of May 6, 2026, 92.60% of the company's stock is owned by institutional shareholders, 7.40% by insiders, and 0.00% by retail investors. Major institutional owners include Fmr Llc, BlackRock, Inc., and Vanguard Group Inc. Fairmount Funds Management LLC is the largest individual shareholder, owning 5.50 million shares.